APA (7th ed.) Citation

Bhargave, S., Sharma, V., Kataria, B., Batra, A., Pushpam, D., Sharma, A., . . . Kumar, A. Olanzapine Versus NK1 Receptor Antagonist for Prevention of Carboplatin-Induced (AUC ≥4) Emesis: A Phase III, Double-Blind, Placebo-Controlled Randomized Trial From India. American Society of Clinical Oncology.

Chicago Style (17th ed.) Citation

Bhargave, Sneh, et al. Olanzapine Versus NK1 Receptor Antagonist for Prevention of Carboplatin-Induced (AUC ≥4) Emesis: A Phase III, Double-Blind, Placebo-Controlled Randomized Trial From India. American Society of Clinical Oncology.

MLA (9th ed.) Citation

Bhargave, Sneh, et al. Olanzapine Versus NK1 Receptor Antagonist for Prevention of Carboplatin-Induced (AUC ≥4) Emesis: A Phase III, Double-Blind, Placebo-Controlled Randomized Trial From India. American Society of Clinical Oncology.